Home Latest Articles
Latest Articles
  • Wei-sheng TIAN, Ya-ru YAN, Xiao-xue CUI, Ying-xia WANG, Wen-qian HUANG, Sai-jing ZHAO, Jun LI, She-po SHI, Peng-fei TU, Xiao LIU
    Acta Pharmaceutica Sinica. 2024, 59(11): 3153-3163.

    Sucrose synthase plays a crucial role in the plant sugar metabolism pathway by catalyzing the production of uridine diphosphate (UDP)-glucose, which serves as a bioactive glycosyl donor for various metabolic processes. In this study, a sucrose synthase gene named CtSus was cloned from Cistanche tubulosa, a traditional Chinese medicine known for its rich content of diverse glycosides, based on transcriptome analysis results. The open reading frame of CtSus was 2 418 bp long encoding 805 amino acids. Sequence analysis revealed conserved domains associated with the plant sucrose synthase family at both the N-terminal and C-terminal regions of CtSus protein. Phylogenetic analysis demonstrated that CtSus shares a close evolutionary relationship with sucrose synthases from other plants within the same order. Functional identification of CtSus was performed through whole-cell catalysis coupling with UGT71BD1, a characterized glycosyltransferase enzyme. The results showed that the introduction of CtSus significantly enhanced the conversion rate of glycosylation catalyzed by UGT71BD1. The soluble expression of CtSus in Escherichia coli was further achieved using the pColdTM TF expression vector. In vitro enzymatic assay indicated the activity of CtSus to catalyze the formation of UDP-glucose in the presence of sucrose and UDP. Real-time quantitative-polymerase chain reaction results showed that the expression patterns of CtSus gene in different parts of C. tubulosa and the suspension cell cultures of C. tubulosa under drought stress correlated with the accumulation patterns observed for phenylethanol glycosides, respectively. Furthermore, key amino acids and their interactions between enzyme and substrate were explored based on protein structure prediction and molecular docking results. Overall, our findings identify a sucrose synthase CtSus responsible for the supply of the active glycosyl donor UDP-glucose during the biosynthesis of glycoside products in C. tubulosa and have also provided a gene element that can be utilized in engineering strain construction for glycoside products production.

  • Yao XIONG, Ling-fei TONG, Lan CAO, Ze-jing MU, Cheng-ying SHEN, Xiao-lang DU
    Acta Pharmaceutica Sinica. 2024, 59(11): 3164-3171.

    Lonicera Linn. is the largest genus of family Caprifoliaceae, which has a long history and abundant resources in China. Due to its ornamental and medicinal properties, the species of Lonicera shows outstanding economic value. However, affected by the huge demand and high price stimulation, there is a serious mixing phenomenon on the market. In this study, high-throughput sequencing technology was used to analyze the analysis of L. angustifolia Wallich ex Candolle var. myrtillus (Hook. f. & Thomson) Q. E. Yang, L. myrtillus Hook. f. et Thoms. var. cyclophylla Rehd, L. szechuanica Batal and L. tangutica Maxim to sequence and assemble their chloroplast (CP) genomes, and to conduct structural comparisons and phylogenetic studies. The results showed that the chloroplast genomes of the four species showed a typical circular tetrad structure, with a total length of 154 608-163 413 bp and a total GC content of 37.93%-38.42%. A total of 128-129 genes were annotated, including 83-84 protein-coding genes, 8 rRNA genes, and 37 tRNA genes. A total of 53-68 SSRs and 133-745 long repeats were detected by chloroplast repeat structure analysis. Phylogenetic studies showed that 21 species of Lonicera medicinal plants could be significantly clustered into one branch, among which the relatives of L. angustifolia and L. szechuanica were close, and the kinship of L. myrtillus and L. tangutica was close. This study is the first comprehensive study of the chloroplast genome and phylogenetic relationship of Loicera species, and the experimental results provide a scientific basis for revealing the genetic information, species evolution and genetic diversity of Lonicera species.

  • Zong-ru GUO
    Acta Pharmaceutica Sinica. 2024, 59(10): 2677-2696.

    Small molecule drugs comprise multi-dimensional features, and drug creation has to meet requirements such as safety, effectiveness, stability, controllability, and patient compliance. These attributes can be summarized as pharmacological activity and druglikeness, which are implicit in the chemical structure of the drug. Pharmacological activity and adverse reactions are caused by the interaction between drug molecules and on-target or off-target protein. The microstructure of the drug determines the activity/toxicity intensity and selectivity. Pharmacokinetic and physicochemical properties are related to the macroscopic properties of the drug, and the microstructure and macroscopic properties are intertwined and integrated into the molecular structure. Conception and construction of bifunctional molecules are one of routes to achieve "unification of micro and macro" and structurally straighten out the relationship between pharmacodynamics-pharmacokinetics, drug efficacy-adverse reactions (selectivity). This article takes drugs that have been successfully marketed or under clinical trials as examples to explain the structural characteristics of bifunctional molecules from the viewpoint of medicinal chemistry. The productive technical methods include antibody-drug conjugate, proteolysis-targeting chimeras, molecular glues, peptide modifications, and so on. In addition, this overview also classifies covalently binding drugs, transition-state analogs, and prodrugs into the category of bifunctional molecules, emphasizing the importance of bifunctional groups in molecular design and structure optimization.

  • Hong-xuan LI, Ying WANG, Ju-xian WANG
    Acta Pharmaceutica Sinica. 2024, 59(10): 2697-2708.

    Pancreatic cancer is one of the most lethal malignant tumors. While the existing surgical resection and chemotherapy have failed to improve the prognosis of patients well, it is urgent to find safer and more effective therapies to meet the clinical therapeutic needs. Antibody drug conjugate (ADC) is a class of targeted antitumor agents that combines monoclonal antibodies with small molecule cytotoxic drugs via chemical linkers. ADC provided wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties which depended on their characteristics of high selectivity, high efficacy and low toxicity. In recent years, the successful application of ADC in the treatment of multiple tumors has aroused a research upsurge in ADC for pancreatic cancer. This review summarizes the structure and mechanism of ADC and the current status of ADC for pancreatic cancer in order to provide some references for the future development of ADC for pancreatic cancer.

  • Bo LI, Hai-yan YAN, Yu-huan LI
    Acta Pharmaceutica Sinica. 2024, 59(10): 2709-2716.

    Influenza virus hemagglutinin (HA) is a key factor in the virus's invasion of host cells, involving the binding of the virus to target cells and the fusion of membranes. The proteolytic cleavage and activation of HA by host proteases are prerequisites for the virus to recognize host cells and initiate membrane fusion, and are also essential for viral infection of the host. This article summarizes the proteolytic activation of different subtypes of influenza virus HA by type Ⅱ transmembrane serine proteases, human tissue kallikreins, and other host proteases, and discusses their potential as targets for antiviral therapy.

  • Qing-yang ZHANG, Quan ZHANG, Li-wei HAN
    Acta Pharmaceutica Sinica. 2024, 59(10): 2717-2722.

    Synthetic medicinal chemistry plays a crucial role in the research and development of new drugs. This article overviewed the proposal application and funding of the General Program, Young Scientist Fund and Fund for Less Developed Regions of National Natural Science Foundation of China related to synthetic medicinal chemistry in application codes H3401 and H3407 in 2023. It also analyzed the hotspots of the applied projects of synthetic medicinal chemistry in 2023 and provided suggestions to address the current challenges, which aimed to further exert the role of synthetic medicinal chemistry in the development of new drugs and continuously promote the high-quality development of China's original new drug research.

  • Li-ling HUANG, Yu-qiong KONG, Heng-yuan MA
    Acta Pharmaceutica Sinica. 2024, 59(10): 2723-2729.

    Drug testing involves many analytical instruments and test items, sample pretreatment is tedious, the industry's intelligence level remains low, making drug testing a labour-intensive job. However, in the era of Industry 4.0 intelligent manufacturing, intelligent transformation of the quality control (QC) laboratory has become the focus of industry. At the same time, driven by consistency evaluation of the quality and efficacy of generic drugs and the centralized procurement policies, pharmaceutical companies have intensified their competition, further stimulating the intrinsic demand for laboratory intelligence. Based on the current state and future trends of the pharmaceutical industry, this review discusses the development of a digital and automated QC laboratory. It points out the necessity of transitioning from the traditional centralized laboratory model to an intelligent, distributed quality control model to accommodate continuous manufacturing processes. At the same time, it also analyses the potential challenges in the implementation process and coping strategies, in order to provide relevant practitioners with ideas for building intelligent QC laboratories.

  • Wen-jing BAI, Rong GUO, Lin XIONG, Leng-jing ZHU, Jia-xin LI, Ya-shi WANG, Man LI, Qin HE
    Acta Pharmaceutica Sinica. 2024, 59(10): 2730-2740.

    Pulmonary disease is one of the major threats to human health. However, the current clinical treatment drugs for lung diseases generally have problems such as low lung delivery efficiency, fast clearance rate and obvious toxic side effects. Recently, membrane biomimetic nanocarriers have attracted more and more attention. Due to their advantages of high targeting, long cycle time, good biocompatibility and strong immune escape ability, membrane biomimetic nanocarriers have become a major research hotspot in targeted therapy of lung diseases. In this review, we discuss the main preparation methods of membrane biomimetic nanoparticles, the characteristics of membrane biomimetic nanocarriers from different cell sources and their application in the targeted therapy of lung diseases. At the same time, according to the characteristics of different membranes, the shortcomings, current technical limitations and future prospects are discussed. This review is expected to provide references for the design of membrane biomimetic nanocarriers and their potential applications in the treatment of lung diseases.

  • Zeng-lin YIN, Xi-wei WANG, Jin-jing CHE, Nan LIU, Hui ZHANG, Zeng-ming WANG, Jian-chun LI, Ai-ping ZHENG
    Acta Pharmaceutica Sinica. 2024, 59(10): 2741-2750.

    DNA origami is a powerful technique for generating nanostructures with dynamic properties and intelligent controllability. The precise geometric shapes, high programmability, and excellent biocompatibility make DNA origami nanostructures an emerging drug delivery vehicle. The shape, size of the carrier material, as well as the loading and release of drugs are important factors affecting the bioavailability of drugs. This paper focuses on the controllable design of DNA origami nanostructures, efficient drug loading, and intelligent drug release. It summarizes the cutting-edge applications of DNA origami technology in biomedicine, and discusses areas where researchers can contribute to further advancing the clinical application of DNA origami carriers.

  • Han LIU, Guo-zhong YANG, Wan-ren DU, Suo-hui ZHANG, Ze-quan ZHOU, Yun-hua GAO
    Acta Pharmaceutica Sinica. 2024, 59(10): 2751-2762.

    As a new transdermal drug delivery system, microneedles can significantly improve skin permeability, enhance drug transdermal delivery, and demonstrate unique advantages in breaking stratum corneum barrier of skin. This feature enables microneedles to demonstrate enormous potential in delivering biotechnology drugs. The traditional delivery method for biotechnology drugs is mainly injection, which brings problems such as pain and skin redness to patients, leading to poor patient compliance. In addition, the production, transportation, and storage of biotechnology drugs require strict low-temperature conditions to maintain their activity and increase cost output. Microneedles, by contrast, have many benefits, providing new avenues and solutions for biomolecular delivery. Accordingly, this review introduced the microneedle drug delivery system for delivery biotechnology drugs, and summarized the research progress of microneedle systems in biotechnology drugs.